S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Xtalks Unveils August 2026 Life Science Webinar Schedule

Toronto-based platform Xtalks has released its August 2026 calendar, featuring a series of free educational webinars focused on clinical trials, drug safety, and laboratory innovation. These sessions, led by industry experts, aim to address emerging challenges in the pharmaceutical, biotechnology, and medical device sectors through collaborative professional discussion.

Xtalks Unveils August 2026 Life Science Webinar Schedule
Photo: Bio & News

The upcoming schedule highlights a shift toward digital integration and artificial intelligence within life science workflows. Key presentations include August 20's focus on biomarker-driven precision oncology and the August 26 session regarding the role of AI in reducing risks within eClinical environments. The program also tackles logistical hurdles, such as preventing pharmacy copay misuse on August 24 and navigating the transition from animal testing to new approach methodologies on August 27.

Laboratory technology remains a cornerstone of the month's agenda. Experts will cover topics ranging from automated cell culture media development on August 12 to spatial proteomic panel development on August 25. Additionally, the series addresses patient-centric research, with sessions on August 5 and 17 dedicated to optimizing global recruitment strategies and community-based trial delivery models. Registration for all events is currently open through the Xtalks portal.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!